AnaptysBio (ANAB)

• Market cap: $1.62B
• 1 day: 0.74%
• 5 days: 9.27%
• 1 month: -17.31%
• 3 months: -18.08%
• 6 months: 9.69%
• Year to date: 21.36%
• 1 year: 105.15%
• 5 years: 127.1%
• 10 years: 220.88%
• Sector: Healthcare
• Industry: Biotechnology

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 104